Kadmon Announces Data Demonstrating the Potential of the Company’s New GLUT Inhibitors for the Treatment of Autoimmune & In...
June 01 2017 - 09:00AM
Business Wire
-- Preclinical Data to be Presented at Keystone
Symposia on Integrating Metabolism and Immunity --
Kadmon Holdings, Inc. (NYSE:KDMN) (“Kadmon” or the “Company”)
today announced preclinical data demonstrating the potential of the
Company’s new glucose transporter (GLUT) inhibitors to treat
autoimmune and inflammatory conditions. These are the first
findings to be presented from Kadmon’s GLUT inhibitor program,
which will be shared as a poster at the Keystone Symposia on
Integrating Metabolism and Immunity today in Dublin, Ireland.
“Unlike normal cells, activated immune cells are highly reliant
on glucose uptake for their activity,” said Masha Poyurovsky, PhD,
Vice President, Head of Molecular Signaling at Kadmon and senior
author of the study. “We confirmed that by cutting off this
nutrient supply for immune cells, we can selectively affect
pro-inflammatory activity to rebalance the overactive immune
response and potentially resolve inflammation.”
Marked increase in glucose consumption is a well-characterized
and requisite component of immune cell growth and activation.
Kadmon researchers have developed potent, oral inhibitors of
glucose transport, with the aim of blocking aberrant immune cell
activity. The Company’s GLUT inhibitors have a good pharmacokinetic
profile and directly block glucose uptake. Experiments in isolated
human T cells demonstrated that these GLUT inhibitors blocked the
secretion of pro-inflammatory cytokines, such as IL-17 and
TNF-alpha, and modulated key intracellular signaling pathways in
pathogenic T cells, including STAT1, STAT3 and S6K. Importantly,
these GLUT inhibitors were well tolerated and reduced inflammation
in mouse models at therapeutically relevant doses. These findings
provide the foundation to advance Kadmon’s GLUT inhibitors toward
clinical development.
“These data from Kadmon’s GLUT inhibitor program describe an
important new approach to treating autoimmune and inflammatory
disease,” said Lawrence K. Cohen, Ph.D., Executive Vice President,
Business Development at Kadmon. “Immunometabolism represents a
promising area of future research and development at Kadmon and a
potential novel pharmacological intervention in autoimmune and
inflammatory disease.”
About Kadmon Holdings, Inc.
Kadmon Holdings, Inc. is a fully integrated biopharmaceutical
company focused on developing innovative products for significant
unmet medical needs. We have a diversified product pipeline in
autoimmune and fibrotic diseases, oncology and genetic
diseases.
Safe Harbor Statement
This press release contains forward-looking statements. Such
statements may be preceded by the words “may,” “will,” “should,”
“expects,” “plans,” “anticipates,” “could,” “intends,” “targets,”
“projects,” “contemplates,” “believes,” “estimates,” “predicts,”
“potential” or “continue” or the negative of these terms or other
similar expressions. Forward-looking statements involve known and
unknown risks, uncertainties and other important factors that may
cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. We believe that these factors include, but are not
limited to, (i) the initiation, timing, progress and results of our
preclinical studies and clinical trials, and our research and
development programs; (ii) our ability to advance product
candidates into, and successfully complete, clinical trials; (iii)
our reliance on the success of our product candidates; (iv) the
timing or likelihood of regulatory filings and approvals; (v) our
ability to expand our sales and marketing capabilities; (vi) the
commercialization of our product candidates, if approved; (vii) the
pricing and reimbursement of our product candidates, if approved;
(viii) the implementation of our business model, strategic plans
for our business, product candidates and technology; (ix) the scope
of protection we are able to establish and maintain for
intellectual property rights covering our product candidates and
technology; (x) our ability to operate our business without
infringing the intellectual property rights and proprietary
technology of third parties; (xi) costs associated with defending
intellectual property infringement, product liability and other
claims; (xii) regulatory developments in the United States, Europe
and other jurisdictions; (xiii) estimates of our expenses, future
revenues, capital requirements and our needs for additional
financing; (xiv) the potential benefits of strategic collaboration
agreements and our ability to enter into strategic arrangements;
(xv) our ability to maintain and establish collaborations or obtain
additional grant funding; (xvi) the rate and degree of market
acceptance of our product candidates; (xvii) developments relating
to our competitors and our industry, including competing therapies;
(xviii) our ability to effectively manage our anticipated growth;
(xix) our ability to attract and retain qualified employees and key
personnel; (xx) our ability to achieve cost savings and other
benefits from our efforts to streamline our operations and to not
harm our business with such efforts; and (xxi) the use of proceeds
from our recent private placement. More detailed information about
Kadmon and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's filings
with the U.S. Securities and Exchange Commission (SEC), including
the Company's Quarterly Report on Form 10-Q filed pursuant to
Section 13 of the Securities Exchange Act of 1934, as amended, with
the SEC on May 15, 2017. Investors and security holders are urged
to read these documents free of charge on the SEC's web site at
www.sec.gov. The Company assumes no obligation to publicly update
or revise its forward-looking statements as a result of new
information, future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170601005242/en/
Kadmon Holdings, Inc.Ellen Tremaine, 646-490-2989Investor
Relationsellen.tremaine@kadmon.comorMaeve Conneighton,
212-600-1902maeve@argotpartners.com
Kadmon (NYSE:KDMN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Kadmon (NYSE:KDMN)
Historical Stock Chart
From Mar 2023 to Mar 2024